3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Neoplasm Metastasis
3
Uterine Cervical Neoplasms
2
Neoplasms
2
Camurati-Engelmann Syndrome
2
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Nasopharyngeal Carcinoma
1
Microsatellite Instability
1
Metastatic Solid Tumors
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Anatomic Stage II Breast Cancer AJCC v8
1
Interventions
Pemetrexed
23
Cisplatin
19
Nivolumab
8
Gemcitabine
7
Ipilimumab
6
Carboplatin
6
pembrolizumab
4
Bevacizumab
4
tazemetostat
3
durvalumab
3
Fluorouracil
3
Drug Therapy
3
spartalizumab
2
olaparib
2
niraparib
2
budigalimab
2
belinostat
2
anetumab ravtansine
2
amatuximab
2
Vinorelbine
2
Radiotherapy, Intensity-Modulated
2
Paclitaxel
2
PM 01183
2
Oxaliplatin
2
Imatinib Mesylate
2
Everolimus
2
Erlotinib Hydrochloride
2
Doxorubicin
2
Cyclophosphamide
2
venetoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Mesothelioma
×
bintrafusp alfa protein, human
×
Clear all
NCT05005429
2025-12-23
BIMES
Fundación GECP
Phase 2
Completed
47 enrolled
9 charts